Related references
Note: Only part of the references are listed.Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies
Su-Hyun Kim et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)
Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study
Renata Barbosa Paolilo et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Incidence of interattack asymptomatic brain lesions in NMO spectrum disorder
Min Young Lee et al.
NEUROLOGY (2020)
Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders
Jacqueline Palace et al.
BRAIN (2019)
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Bruce A. C. Cree et al.
LANCET (2019)
Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes
Sophie Duignan et al.
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2018)
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Dean M. Wingerchuk et al.
NEUROLOGY (2015)
Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders
Douglas Kazutoshi Sato et al.
NEUROLOGY (2013)
Share Paper
